Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
Introduction:For metastatic prostate cancer (PC), androgen deprivation therapy (ADT) is the primary treatment option. Most patients develop resistance, after an initial response to treatment. This study aimed to evaluate real-life data of first-line docetaxel treatment for metastatic castration-resi...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2022-11-01
|
| Series: | İstanbul Medical Journal |
| Subjects: | |
| Online Access: |
http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/time-to-castration-resistance-as-a-predictor-of-re/56436
|
| _version_ | 1797921224767045632 |
|---|---|
| author | İlkay Gültürk Gülçin Şahingöz Erdal Gülru Birce Sönmezoz Mesut Yılmaz Seher Yıldız Tacar Aykut Özmen Deniz Tataroğlu Özyükseler Özgecan Dulgar İbrahim Çil Deniz Tural |
| author_facet | İlkay Gültürk Gülçin Şahingöz Erdal Gülru Birce Sönmezoz Mesut Yılmaz Seher Yıldız Tacar Aykut Özmen Deniz Tataroğlu Özyükseler Özgecan Dulgar İbrahim Çil Deniz Tural |
| author_sort | İlkay Gültürk |
| collection | DOAJ |
| description | Introduction:For metastatic prostate cancer (PC), androgen deprivation therapy (ADT) is the primary treatment option. Most patients develop resistance, after an initial response to treatment. This study aimed to evaluate real-life data of first-line docetaxel treatment for metastatic castration-resistant prostate cancer (mCRPC) and analyzed whether the response time to ADT could predict the response to docetaxel treatment.Methods:The study included 111 patients with mCRPC who were treated with docetaxel. Time to castration resistance (TTCR) was defined as the time from initiation to the failure of primary ADT. Patients were divided into two groups based on TTCR. Patients with TTCR ≤12 months were assigned to group 1, while patients with TTCR >12 months were assigned to group 2.Results:The median overall survival (OS) of the patients in group 1 was 16 months, whereas the median OS in group 2 was 38 months. Group 2 had a statistically significantly longer OS than group 1 (p<0.001). The median progression-free survival (PFS) of the patients in group 2 was 14 months while the median PFS in group 1 was 7 months. Group 2 had a statistically significantly longer PFS than group 1 (p<0.001). TTCR, Gleason score, and liver metastasis parameters were found to be predictive factors for OS.Conclusion:In patients with mCRPC, TTCR was found to be a predictor of OS and PFS who were treated with docetaxel. |
| first_indexed | 2024-04-10T14:13:08Z |
| format | Article |
| id | doaj.art-4fd073773cc34e1c9b30ce4d1b0e41c1 |
| institution | Directory Open Access Journal |
| issn | 2619-9793 2148-094X |
| language | English |
| last_indexed | 2024-04-10T14:13:08Z |
| publishDate | 2022-11-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | İstanbul Medical Journal |
| spelling | doaj.art-4fd073773cc34e1c9b30ce4d1b0e41c12023-02-15T16:09:38ZengGalenos Yayineviİstanbul Medical Journal2619-97932148-094X2022-11-0123426927410.4274/imj.galenos.2022.5680413049054Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancerİlkay Gültürk0Gülçin Şahingöz Erdal1Gülru Birce Sönmezoz2Mesut Yılmaz3Seher Yıldız Tacar4Aykut Özmen5Deniz Tataroğlu Özyükseler6Özgecan Dulgar7İbrahim Çil8Deniz Tural9 University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Turkey University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Turkey University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Internal Medicine, İstanbul, Turkey University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Turkey University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Turkey University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Turkey University of Health Sciences Turkey, Kartal Dr. Lütfi Kırdar City Hospital, Clinic of Medical Oncology, İstanbul, Turkey Kahramanmaraş Necip Fazıl City Hospital, Clinic of Medical Oncology, İstanbul, Turkey University of Health Sciences Turkey, Ümraniye Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Turkey University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Turkey Introduction:For metastatic prostate cancer (PC), androgen deprivation therapy (ADT) is the primary treatment option. Most patients develop resistance, after an initial response to treatment. This study aimed to evaluate real-life data of first-line docetaxel treatment for metastatic castration-resistant prostate cancer (mCRPC) and analyzed whether the response time to ADT could predict the response to docetaxel treatment.Methods:The study included 111 patients with mCRPC who were treated with docetaxel. Time to castration resistance (TTCR) was defined as the time from initiation to the failure of primary ADT. Patients were divided into two groups based on TTCR. Patients with TTCR ≤12 months were assigned to group 1, while patients with TTCR >12 months were assigned to group 2.Results:The median overall survival (OS) of the patients in group 1 was 16 months, whereas the median OS in group 2 was 38 months. Group 2 had a statistically significantly longer OS than group 1 (p<0.001). The median progression-free survival (PFS) of the patients in group 2 was 14 months while the median PFS in group 1 was 7 months. Group 2 had a statistically significantly longer PFS than group 1 (p<0.001). TTCR, Gleason score, and liver metastasis parameters were found to be predictive factors for OS.Conclusion:In patients with mCRPC, TTCR was found to be a predictor of OS and PFS who were treated with docetaxel. http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/time-to-castration-resistance-as-a-predictor-of-re/56436 prostate cancerandrogen deprivation therapydocetaxelmetastatic castration-resistant prostate cancer |
| spellingShingle | İlkay Gültürk Gülçin Şahingöz Erdal Gülru Birce Sönmezoz Mesut Yılmaz Seher Yıldız Tacar Aykut Özmen Deniz Tataroğlu Özyükseler Özgecan Dulgar İbrahim Çil Deniz Tural Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer İstanbul Medical Journal prostate cancer androgen deprivation therapy docetaxel metastatic castration-resistant prostate cancer |
| title | Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer |
| title_full | Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer |
| title_fullStr | Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer |
| title_full_unstemmed | Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer |
| title_short | Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer |
| title_sort | time to castration resistance as a predictor of response to docetaxel in metastatic castration resistance in prostate cancer |
| topic | prostate cancer androgen deprivation therapy docetaxel metastatic castration-resistant prostate cancer |
| url |
http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/time-to-castration-resistance-as-a-predictor-of-re/56436
|
| work_keys_str_mv | AT ilkaygulturk timetocastrationresistanceasapredictorofresponsetodocetaxelinmetastaticcastrationresistanceinprostatecancer AT gulcinsahingozerdal timetocastrationresistanceasapredictorofresponsetodocetaxelinmetastaticcastrationresistanceinprostatecancer AT gulrubircesonmezoz timetocastrationresistanceasapredictorofresponsetodocetaxelinmetastaticcastrationresistanceinprostatecancer AT mesutyılmaz timetocastrationresistanceasapredictorofresponsetodocetaxelinmetastaticcastrationresistanceinprostatecancer AT seheryıldıztacar timetocastrationresistanceasapredictorofresponsetodocetaxelinmetastaticcastrationresistanceinprostatecancer AT aykutozmen timetocastrationresistanceasapredictorofresponsetodocetaxelinmetastaticcastrationresistanceinprostatecancer AT deniztatarogluozyukseler timetocastrationresistanceasapredictorofresponsetodocetaxelinmetastaticcastrationresistanceinprostatecancer AT ozgecandulgar timetocastrationresistanceasapredictorofresponsetodocetaxelinmetastaticcastrationresistanceinprostatecancer AT ibrahimcil timetocastrationresistanceasapredictorofresponsetodocetaxelinmetastaticcastrationresistanceinprostatecancer AT deniztural timetocastrationresistanceasapredictorofresponsetodocetaxelinmetastaticcastrationresistanceinprostatecancer |